Figure 1

Absolute number of circulating monocytes, and the numbers of their subset cells, in naive patients with RA at baseline and over MTX treatment. Absolute number (cells/μl) of circulating monocytes (panel A), and the numbers of CD14^+highCD16⁻ (panel B), CD14^+highCD16⁺ (panel C) and CD14^+lowCD16⁺ monocytes (panel D) in non-responders (■) and responders (○) at baseline and after 3 and 6 months of MTX treatment, and of healthy controls (▼), are shown as means ± SEM. *Significant difference at baseline between groups (patients with RA and healthy controls [or responders and non-responders]). ^†significant difference between responders and non-responders over the studied period. ^‡Significant difference between baseline and 6 month values.